ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
02 2019
Historique:
received: 18 01 2018
accepted: 20 10 2018
pubmed: 28 11 2018
medline: 27 2 2019
entrez: 28 11 2018
Statut: ppublish

Résumé

Bone is the most common metastatic site for breast cancer. Estrogen-related-receptor alpha (ERRα) has been implicated in cancer cell invasiveness. Here, we established that ERRα promotes spontaneous metastatic dissemination of breast cancer cells from primary mammary tumors to the skeleton. We carried out cohort studies, pharmacological inhibition, gain-of-function analyses in vivo and cellular and molecular studies in vitro to identify new biomarkers in breast cancer metastases. Meta-analysis of human primary breast tumors revealed that high ERRα expression levels were associated with bone but not lung metastases. ERRα expression was also detected in circulating tumor cells from metastatic breast cancer patients. ERRα overexpression in murine 4T1 breast cancer cells promoted spontaneous bone micro-metastases formation when tumor cells were inoculated orthotopically, whereas lung metastases occurred irrespective of ERRα expression level. In vivo, Rank was identified as a target for ERRα. That was confirmed in vitro in Rankl stimulated tumor cell invasion, in mTOR/pS6K phosphorylation, by transactivation assay, ChIP and bioinformatics analyses. Moreover, pharmacological inhibition of ERRα reduced primary tumor growth, bone micro-metastases formation and Rank expression in vitro and in vivo. Transcriptomic studies and meta-analysis confirmed a positive association between metastases and ERRα/RANK in breast cancer patients and also revealed a positive correlation between ERRα and BRCA1

Identifiants

pubmed: 30478447
doi: 10.1038/s41388-018-0579-3
pii: 10.1038/s41388-018-0579-3
doi:

Substances chimiques

Neoplasm Proteins 0
Receptor Activator of Nuclear Factor-kappa B 0
Receptors, Estrogen 0
TNFRSF11A protein, human 0
Tnfrsf11a protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

950-964

Références

Cancer Res. 2010 Nov 15;70(22):9298-308
pubmed: 20870744
Oncotarget. 2016 Nov 22;7(47):77071-77086
pubmed: 27776343
J Clin Oncol. 2003 Mar 15;21(6):984-90
pubmed: 12637461
J Clin Pathol. 2012 Jan;65(1):36-40
pubmed: 22049226
Nature. 1988 Jan 7;331(6151):91-4
pubmed: 3267207
Clin Exp Metastasis. 2014 Feb;31(2):233-45
pubmed: 24272640
Mol Endocrinol. 2016 Jul;30(7):809-25
pubmed: 27182621
J Mol Endocrinol. 2010 Dec;45(6):365-77
pubmed: 20841427
Nat Med. 2016 Aug;22(8):933-9
pubmed: 27322743
Int J Mol Sci. 2016 Oct 04;17(10):
pubmed: 27782035
Endocrinology. 2009 Oct;150(10):4463-72
pubmed: 19608650
Nature. 2003 May 15;423(6937):337-42
pubmed: 12748652
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8912-7
pubmed: 15184675
Nature. 2006 Mar 30;440(7084):692-6
pubmed: 16572175
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Am J Physiol Endocrinol Metab. 2018 Feb 1;314(2):E115-E123
pubmed: 29018002
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):106-12
pubmed: 19429439
Cancer Res. 2002 Nov 15;62(22):6510-8
pubmed: 12438245
PLoS One. 2011 Apr 29;6(4):e19234
pubmed: 21559440
Acta Pharmacol Sin. 2015 Jan;36(1):51-61
pubmed: 25500872
Nature. 2005 Jul 28;436(7050):518-24
pubmed: 16049480
Cell Metab. 2010 Jun 9;11(6):503-16
pubmed: 20519122
J Bone Miner Res. 2015 Dec;30(12):2287-99
pubmed: 26094846
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3909-3914
pubmed: 28348226
Cancer Cell. 2009 Jul 7;16(1):67-78
pubmed: 19573813
Biochem Biophys Res Commun. 2005 Mar 4;328(1):165-72
pubmed: 15670765
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D535-9
pubmed: 16381927
Nucleic Acids Res. 2017 Jan 4;45(D1):D61-D67
pubmed: 27924024
Nat Commun. 2016 Jul 12;7:12156
pubmed: 27402251
Cancer Lett. 2018 Dec 1;438:32-43
pubmed: 30201302
J Clin Endocrinol Metab. 2003 May;88(5):2309-17
pubmed: 12727990
Cancer Res. 2011 Sep 1;71(17):5728-38
pubmed: 21734015
Int J Oncol. 2012 Apr;40(4):1133-41
pubmed: 22200658
Cancer Res. 2001 Feb 15;61(4):1652-8
pubmed: 11245479
Lancet. 2005 Feb 19-25;365(9460):671-9
pubmed: 15721472
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Pharmacol Rev. 2006 Dec;58(4):798-836
pubmed: 17132856
Biochim Biophys Acta. 2016 Aug;1866(1):23-36
pubmed: 27264242
Cancer Res. 2015 Dec 15;75(24):5367-77
pubmed: 26573792
Nat Rev Cancer. 2013 Jan;13(1):27-36
pubmed: 23192231
Nature. 2009 Jun 18;459(7249):1005-9
pubmed: 19421193
PLoS Biol. 2012 Jul;10(7):e1001363
pubmed: 22815651
J Bone Miner Res. 2013 Feb;28(2):225-33
pubmed: 23212690
Cancer Treat Rev. 2017 Dec;61:23-34
pubmed: 29100167
J Med Chem. 2011 Feb 10;54(3):788-808
pubmed: 21218783
Mol Endocrinol. 2006 May;20(5):1035-47
pubmed: 16439465
N Engl J Med. 2002 Dec 19;347(25):1999-2009
pubmed: 12490681
J Natl Cancer Inst. 1995 Aug 2;87(15):1162-8
pubmed: 7674321
J Clin Invest. 2017 Jun 30;127(7):2555-2568
pubmed: 28530645
Cancer Res. 1992 Mar 15;52(6):1399-405
pubmed: 1540948
Cell Res. 2016 Jul;26(7):761-74
pubmed: 27241552
J Steroid Biochem Mol Biol. 2016 Mar;157:13-9
pubmed: 26151739
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17975-80
pubmed: 24127579
Cell Metab. 2013 Apr 2;17(4):586-98
pubmed: 23562079
J Clin Invest. 2018 Mar 1;128(3):1087-1105
pubmed: 29431735
J Bone Oncol. 2017 Sep 11;9:1-9
pubmed: 28948139
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Nat Rev Drug Discov. 2012 May;11(5):401-19
pubmed: 22543469
J Clin Oncol. 2008 Jul 1;26(19):3153-8
pubmed: 18490649

Auteurs

G Vargas (G)

INSERM-UMR1033, Lyon, France.
University of Lyon1, Lyon, France.

M Bouchet (M)

INSERM-UMR1033, Lyon, France.
University of Lyon1, Lyon, France.
IGFL, Lyon, France.

L Bouazza (L)

INSERM-UMR1033, Lyon, France.
University of Lyon1, Lyon, France.

P Reboul (P)

UMR7365-CNRS-Université de Lorraine, Nancy, France.

C Boyault (C)

Institute for Advanced Biosciences, Grenoble, France.

M Gervais (M)

INSERM-UMR1033, Lyon, France.
University of Lyon1, Lyon, France.

C Kan (C)

INSERM-UMR1033, Lyon, France.
University of Lyon1, Lyon, France.
Center for Cancer Research, University of Sydney, Sydney, Australia.

C Benetollo (C)

University of Lyon1, Lyon, France.
INSERM-U1028-CNRS-UMR5292, Lyon, France.

M Brevet (M)

INSERM-UMR1033, Lyon, France.
Centre de Biologie et de Pathologie Est, Bron, France.

M Croset (M)

INSERM-UMR1033, Lyon, France.
University of Lyon1, Lyon, France.

M Mazel (M)

EA2415-Institut Universitaire de Recherche Clinique, Montpellier, France.

L Cayrefourcq (L)

EA2415-Institut Universitaire de Recherche Clinique, Montpellier, France.

S Geraci (S)

INSERM-UMR1033, Lyon, France.
University of Lyon1, Lyon, France.

S Vacher (S)

Department of Genetics, Institut-Curie, Paris, France.

F Pantano (F)

University-Campus-Bio-Medico, Rome, 00128, Italy.

M Filipits (M)

Department of Surgery and Comprehensive Cancer Center, Medical-University of Vienna, Vienna, Austria.

K Driouch (K)

Department of Genetics, Institut-Curie, Paris, France.

I Bieche (I)

Department of Genetics, Institut-Curie, Paris, France.

M Gnant (M)

Department of Surgery and Comprehensive Cancer Center, Medical-University of Vienna, Vienna, Austria.

W Jacot (W)

Montpellier Cancer Institute, Montpellier, France.

J E Aubin (JE)

University of Toronto, Toronto, Canada.

M Duterque-Coquillaud (M)

UMR8161/CNRS-Institut de Biologie de Lille, Lille, France.

C Alix-Panabières (C)

EA2415-Institut Universitaire de Recherche Clinique, Montpellier, France.

P Clézardin (P)

INSERM-UMR1033, Lyon, France.
University of Lyon1, Lyon, France.

E Bonnelye (E)

INSERM-UMR1033, Lyon, France. edith.bonnelye@inserm.fr.
University of Lyon1, Lyon, France. edith.bonnelye@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH